TScan Therapeutics Inc. (TCRX)
NASDAQ · Healthcare
TScan Therapeutics Inc. Long Term Debt 2020–2025
TScan Therapeutics Inc. annual/quarterly long term debt history from 2022 to 2025. Long term debt refers to financial obligations that are due more than one year in the future.
- TScan Therapeutics Inc. long term debt for the quarter ending December 31, 2025 were 32.5M, a 1.44% increase year-over-year.
- TScan Therapeutics Inc. long term debt for 2025 were 32.5M, a 1.44% increase from 2024.
- TScan Therapeutics Inc. long term debt for 2024 were 32.1M, a 6.74% increase from 2023.
- TScan Therapeutics Inc. long term debt for 2023 were 30.0M, a 2.58% increase from 2022.
- TScan Therapeutics Inc. long term debt for 2022 were 29.3M.
Long Term Debt
QUARTERLY · $B
YOY QUARTERLY GROWTH · %
| TScan Therapeutics Inc. Annual Long Term Debt (Millions of US $) | |
|---|---|
| 2025 | $33 |
| 2024 | $32 |
| 2023 | $30 |
| 2022 | $29 |
| TScan Therapeutics Inc. Quarterly Long Term Debt (Millions of US $) | |
|---|---|
| 2025-12-31 | $33 |
| 2024-12-31 | $32 |
| 2023-12-31 | $30 |
| 2022-12-31 | $29 |
TScan Therapeutics Inc. Long Term Debt — FAQ
TScan Therapeutics Inc. (TCRX) long term debt over the last 6 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see TCRX's long term debt history?
The chart and table above show TScan Therapeutics Inc.'s long term debt by year and by quarter, including the growth rate.